Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival

P. Sivaramakrishna Rachakonda1,*, Andrea S. Bauer2, Huaping Xie1,3, Daniele Campa1, Cosmeri Rizzato1, Federico Canzian1, Stefania Beghelli4, William Greenhalf5, Eithne Costello5, Michaela Schanne2, Anette Heller6, Aldo Scarpa4, John P. Neoptolemos5, Jens Werner6, Markus Büchler6, Jörg D. Hoheisel2, Kari Hemminki1,7, Nathalia Giese6, Rajiv Kumar1

1 Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany, 2 Division of Functional Genome Analysis, German Cancer Research Center, Heidelberg, Germany, 3 Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 4 Department of Pathology and Diagnostics, Università di Verona, Verona, Italy, 5 National Institute for Health Research, Pancreas Biomedical Research Unit and Cancer Research UK Centre, Liverpool, United Kingdom, 6 Department of General Surgery, University Hospital Heidelberg, Heidelberg, Germany, 7 Center for Primary Health Care Research, Lund University, Malmö, Sweden

Abstract

KRAS mutations are major factors involved in initiation and maintenance of pancreatic tumors. The impact of different mutations on patient survival has not been clearly defined. We screened tumors from 171 pancreatic cancer patients for mutations in KRAS and CDKN2A genes. Mutations in KRAS were detected in 134 tumors, with 131 in codon 12 and only 3 in codon 61. The GGT->GAT (G12D) was the most frequent mutation and was present in 60% (80/134). Deletions and mutations in CDKN2A were detected in 43 tumors. Analysis showed that KRAS mutations were associated with reduced patient survival in both malignant exocrine and ductal adenocarcinomas (PDAC). Patients with PDACs that had KRAS mutations showed a median survival of 17 months compared to 30 months for those without mutations (log-rank test P = 0.07) with a multivariate hazard ratio (HR) of 2.19 (95% CI 1.09–4.42). The patients with G12D mutation showed a median survival of 16 months (log-rank-test P = 0.03) and an associated multivariate HR 2.42 (95% CI 1.14–4.67). Although, the association of survival in PDAC patients with CDKN2A aberrations in tumors was not statistically significant, the sub-group of patients with concomitant KRAS mutations and CDKN2A alterations in tumors were associated with a median survival of 13.5 months compared to 22 months without mutation (log-rank-test P = 0.02) and a corresponding HR of 3.07 (95% CI 1.33–7.10). Our results are indicative of an association between mutational status and survival in PDAC patients, which if confirmed in subsequent studies can have potential clinical application.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the most fatal form of pancreatic malignancy with a 5 year survival of less than 4% [1,2]. Tumor heterogeneity, lack of early detection methods and refractoriness to conventional chemotherapy all contribute to the poor outcome [2]. Surgical resection has limited potential for cure, with less than 20% of patients eligible for surgery with curative intent, due to local spread or metastasis [3]. PDAC is thought to develop from PanIN lesions (pancreatic intraepithelial neoplasia) through progressive accumulation of somatic alterations in critical genes [4,5]. Despite a repertoire of information, studies linking somatic alterations in PDAC with patient survival are lacking.

Over the years somatic mutations have been shown to be legitimate targets for anti-cancer drugs because of casual relationship with tumor formation and maintenance [6]. Historical indistinct tumors, based on the mutational profiles are reported to be differentially amenable to chemotherapeutics [7]. Specific chemotherapeutics, based on mutational status, in colorectal, lung, melanoma and other cancer types are already part of cancer treatments [8–12]. Despite KRAS being the most frequently mutated oncogene in pancreatic cancer with a reported frequency ranging between 20 and 100%, it has not been so far utilized in categorization of tumors for clinical purposes [13]. Though, some previous reports have suggested association of KRAS mutations in resected pancreatic cancers with prognosis [14,15].

Most of the earlier reports on KRAS mutations in pancreatic cancer were based on relatively small tumor numbers that lacked statistical power to determine association with the disease outcome. In order to address the issue of frequency of KRAS mutation in pancreatic cancer and impact of those mutations on disease outcome, we have in this study included a series of fully characterized 171 pancreatic tumors with complete patient data.
Results

The 163 patients with malignant tumors in this study comprised the following: i) 143 ductal adenocarcinomas that also included 5 adenosquamous and 4 anaplastic undifferentiated variants, ii) 16 rare carcinomas that were comprised of 2 acinar cell carcinomas, 2 (microcystic) tubulo-papillary carcinomas, 9 intraductal papillary mucinous neoplasm (IPMN, invasive type), 2 solid pseudopapillary neoplasms (Frantz tumors) and 1 cystadenocarcinoma, and iii) 4 papillary (ampulla of Vater) carcinomas. The non-malignant group was composed of 4 benign lesions in the form of serous cystic adenomas (SCA) and premalignant lesions in the form of 1 mucinous cyst neoplasm (MCN) and 3 non-invasive IPMN (Table 1 and Table S3). All patients except nine received standard Gemcitabine treatment. Out of remaining nine patients, eight received 5-fluorouracil/folinic acid and one patient received 5-fluorouracil and interferon-alpha together with radiation therapy (Table S3).

Mutation detection for KRAS gene was standardized using DNA from cell lines with known KRAS mutation. The sensitivity of SSCP, determined by titration experiments, showed that point mutations in tumor samples up to 5% tumor content were detectable. This provided confidence that our inclusion of tumor samples, only if those had at least 10% tumor content (n = 171), would more than adequately enable the detection of mutations. Another criterion applied for mutation detection was reproducibility. Mutations were scored only when band shifts were reproducible in at least two independent experiments. Repeat experiments using SSCP followed by DNA sequencing were used for confirmation and identification of mutations (Figure S2). We also obtained independent confirmation of KRAS mutations in a random sub-set (n = 6) analyzed blindly in the reference laboratory of the Institute of Pathology, University Hospital of Heidelberg.

In the KRAS gene, we detected 134 mutations in 171 tumors (78%), with 131 mutations in exon 2 and 3 mutations in exon 3 (Table 1). Mutations in exon 2 in all tumors were localized to codon 12. Out of 131 tumors that carried mutation at codon 12, 61% tumors had GGT>GAT (G12D, 80 of 131) mutation, followed by GGT>CGT (G12R, 23 of 131, 18%), GGT>GTT (G12V, 22 of 131, 17%), GGT>TGT (G12C, 4 of 131, 3%), GGT>GCT (G12A, 1 of 131) and GGT>GTC (G12V, 1 of 131). Three tumors carried mutations in exon 3 that were confined to codon 61 featuring the Q61H mutation due to CAA>CAC base change. The mutation frequency in ductal adenocarcinomas was 82% (117 of 143) including adenosquamous and anaplastic undifferentiated tumors. All 4 of the ampulla of Vater tumors showed KRAS mutation, while 7 of 9 IPMN-malignant types harbored mutation (Table 1 and Table S3).

A total of 43 tumors (25%) showed aberrations in the CDKN2A gene. Of the CDKN2A alterations in 43 tumors, 9 carried point mutations and the remainder showed deletion at the locus. All the point mutations in the gene were located in exon 2. Two tumors carried mutation at codon 80 (CGA>TGA, R80*, 3 at codon 83 (CAG>TAC, R83Y), followed by solitary tumors with mutations at codon 58 (CGA>TGA, R58*), codon 129 (TAC>TAA, Y129*), codon 130 (CTG>CAG, L130Q) and one tumor had 2 base pair insertion of GG at codon 78 (CTC>GGTGC). Deletions at the 9p21 locus were detected with varying frequency with 17–20% in the CDKN2A (p16INK4a) and 26–28% within the promoter associated with exon 1B of p14ARF transcript.

Univariate analyses showed that among clinico-pathological factors, only tumor grade significantly affected overall survival in the studied cohort (Table 1). Presence of KRAS mutations tended to shorten survival of patients in general (n = 150; P = 0.07) and in all studied sub-categories (except tumor stage T4), however without reaching statistical significance (Table S2). In 150 patients with malignant exocrine tumors, the activating KRAS mutations were associated with reduction in median survival time nearly by half (17 vs 30 months, Kaplan-Meier method with log-rank test P = 0.07; Figure S3A). The presence of KRAS mutations was associated with poor survival in tumor stage III (HR = 1.94, P = 0.03; Table S2). Risk factors such as smoking, alcohol consumption or diabetes had no effect on patient survival either with or without KRAS mutations. A multivariate Cox regression model that included age, gender, TNM, tumor grade and tumor histology as co-variants confirmed KRAS mutational status as a potential independent prognostic marker with a hazard ratio (HR) of 1.87 (95% CI 0.99–3.51, P = 0.05; Table 2). Analysis with specific types of KRAS mutations at codon 12 showed that the G12D variant was associated with a median survival time of 16 months compared to 30 months for wildtype KRAS (log-rank test, P = 0.02; Figure S3B) and HR of 1.99 (95% CI 1.02–3.90, P = 0.05; multivariate cox-regression analysis; Table 2). Patients with any CDKN2A aberration in tumors showed a shorter median survival time of 13.5 months compared to 19 months in patients without aberrations, however, the difference was not statistically significant (log-rank P = 0.14). The corresponding HR was 1.55 (95% CI 0.97–2.48, P = 0.07; Table 2). The survival of patients with concomitant KRAS mutations and CDKN2A aberrations (n = 31) was poorest with median survival time of 13 months compared to 30 months for patients without any mutations in either KRAS or CDKN2A (log rank P = 0.03; Figure S3C). Out of 31 tumors with concomitant mutations in KRAS and CDKN2A, 30 were stage III or IV. Twenty three of those tumors were lymphnode positive. The HR for the presence of concomitant aberrations in both genes was 2.77 (95% CI 1.23–6.23, P = 0.01; Table 2).

Analysis of survival only for PDAC patients (n = 128) showed a similar association with KRAS mutational status. Patients with KRAS mutations were associated with a median survival time of 17 months compared to 30 months for those without mutations (log-rank test P = 0.07; Figure 1A). Multivariate Cox regression showed association of KRAS mutations with a HR of 2.19 (95% CI 1.09–4.42; Table 3). PDAC patients with G12D mutation in KRAS had 16 months of median survival (log rank P = 0.03; Figure 1B). And the sub-group of PDAC patients with concomitant mutations in KRAS and CDKN2A had a shortest survival of 13.5 months (log rank test P = 0.02; Figure 1C) and a HR of 3.07 (95% CI 1.33–7.10; Table 3).

Discussion

Mutations in KRAS and CDKN2A genes in pancreatic cancer are well documented; however, their influence on disease outcome in patients with exocrine pancreatic tumors has remained unclear. In this study, we observed that KRAS mutation frequency in pancreatic tumors was consistent with ours and other previous European studies that were based on 70–100 tumors and reported a mutation frequency of 72–83% [14,16,17]. Earlier, a Korean study on paraffin embedded 136 tumors reported a mutation frequency of 52% [18]. KRAS mutations in pancreatic cancer are believed to be the early events in neoplastic transformation. The hypothesis is supported by mice models based on conditional endogenous expression of the mutant KRAS. Those mouse models were developed with an assumption that KRAS mutation is an essential and early somatic genetic alteration in PDAC progression. Similar observations were reported for KRAS mutations in human acinar-ductal metaplasia (ADM) lesions of pancreas [19].
### Table 1. Clinical-pathological parameters of pancreatic cancer patients.

|                                | Total (N = 171) | Census status (N = 159) |
|--------------------------------|-----------------|-------------------------|
|                                | Number (%)      | Number (censored)       | Median survival (Months (95% CI)) | Log-rank P * |
| **All categories**             | 159 (93)        | 159 (45)                | 16 (9–26)                          |              |
|                                | 12 (6 no follow up; 6 deaths due to other causes) |                       |                                      |              |
| **Gender**                     |                 |                         |                                      |              |
| Male                           | 100 (58)        | 92 (27)                 | 19 (16–28)                          | 0.19         |
| Female                         | 71 (42)         | 67 (18)                 | 17 (11–22)                          |              |
| **Age at surgery (years)**     | 171             | 159 (45)                | 16 (9–26)                           |              |
|                                | 65 (56–70); Mean = 63 ± 11.31 |                       |                                      |              |
| **Histologic variants**        |                 |                         |                                      |              |
| benign                         |                 |                         |                                      |              |
| Serous cystadenoma, SCA        | 4 (2)           | 4 (4)                   | –                                    |              |
| premalignant                   |                 |                         |                                      |              |
| Mucinous cystic neoplasm, MCN  | 1 (1)           | 1 (1)                   | –                                    |              |
| Intraductal papillary mucinous neoplasm, IPMN (low grade) | 3 (2)           | 1 (1)                   | –                                    |              |
| malignant                      |                 |                         |                                      |              |
| **Ductal adenocarcinomas**     |                 |                         |                                      |              |
| PDAC                           | 134 (78)        | 128 (26)                | 17 (13–22)                          | –            |
| Adenosquamous carcinoma        | 5 (3)           | 4 (0)                   | 13 (3–17)                           | –            |
| Anaplastic undifferentiated carcinoma | 4 (2)   | 3 (0)                   | 3 (2–4)                             | –            |
| **Carcinomas: rare cases**     |                 |                         |                                      |              |
| Acinar cell carcinoma          | 2 (1)           | 2 (2)                   | –                                    | –            |
| Microcystic tubulopapillary adenocarcinoma | 2 (1) | 2 (1)                   | –                                    | –            |
| Intraductal papillary mucinous neoplasm, IPMN (invasive carcinoma) | 9 (5)           | 8 (5)                   | 39 (6–n.c)                          | –            |
| **TNM status**                 |                 |                         |                                      |              |
| **Tumor location**             |                 |                         |                                      |              |
| Carcinoma of ampulla Vateri    | 4 (2)           | 3 (2)                   | –                                    | –            |
| Pancreatic head                | 111 (66)        | 108 (23)                | 17 (13–22)                          | 0.79         |
| Pancreatic body                | 19 (11)         | 15 (4)                  | 22 (5–32)                           |              |
| Pancreatic tail                | 20 (11)         | 19 (8)                  | 19 (8–n.c)                          |              |
| Overlapping sites              | 13 (8)          | 11 (6)                  | 14 (6–n.c)                          |              |
| Ampulla Vateri                 | 4 (2)           | 3 (2)                   | –                                    |              |
| **TNM status**                 |                 |                         |                                      |              |
| **Grade**                      |                 |                         |                                      |              |
| G1                              | 7 (4)           | 6 (1)                   | 24 (5–44)                           | < 0.0001     |
| G2                              | 88 (51)         | 85 (20)                 | 19 (16–24)                          |              |
| G3                              | 57 (33)         | 53 (13)                 | 13 (9–19)                           |              |
| **Anaplastic type**            | 4 (2)           | 3 (0)                   | 2.5 (2–3)                           |              |

* Logrank P-value for the differences in survival.

1 Median survival upper limit not calculable due to insufficient number of events.

doi:10.1371/journal.pone.0060870.t001
Table 2. Multivariate Cox regression analysis for the effect of mutations on survival in malignant exocrine cancer patients.

| Parameter       | Total | Alive (censored) | Median Survival (95% CI) | P   | Hazard ratio (HR)* | 95% CI          |
|-----------------|-------|------------------|--------------------------|-----|-------------------|-----------------|
| KRAS Wt         | 31    | 13               | 30 (13–44)               | 1.00| (reference)       |                 |
| KRAS mutants    | 119   | 24               | 17 (13–21)               | 0.05| 1.87              | 0.99–3.51       |
| KRAS: G12D (GAT) | 70    | 12               | 16 (11–23)               | 0.05| 1.99              | 1.02–3.90       |
| KRAS: G12R (CGT) | 22    | 5                | 18 (13–31)               | 0.93| 1.04              | 0.39–2.75       |
| KRAS: G12V (GTT/GTC) | 20    | 5                | 16 (11–19)               | 0.09| 2.27              | 0.90–5.82       |
| KRAS: Q61H (CAC) | 3     | 0                | 6 (4–35)                 | 0.01| 59.56             | 2.79–1272.33    |
| KRAS: others    | 3     | 2                | –                        | 0.02| 231.44            | 2.27–23560.74   |
| CDKN2A Wt       | 112   | 30               | 19 (16–24)               | 1.00| (reference)       |                 |
| CDKN2A mutants  | 38    | 7                | 13.5 (9–18)              | 0.07| 1.55              | 0.97–2.48       |
| KRAS + CDKN2A wt | 24    | 11               | 30 (13–44)               | 1.00| (reference)       |                 |

* Hazard ratio and corresponding P-value for effect of mutations on survival calculated after adjusting with gender, age, TNM status, tumor differentiation grade and histology.

doi:10.1371/journal.pone.0060870.t002

Figure 1. Kaplan-Meier survival curves showing difference in overall survival in PDAC patients with and without mutations. (A) Median survival of patients with any KRAS mutations was 17 months against 30 months for patients without mutations in the gene. (B) Median survival of patients with KRAS codon 12 GGT→GAT (G12D) mutations was 16 months against 30 months for patients without any mutation in KRAS. (C) Median survival of patients with concomitant alterations in KRAS and CDKN2A genes was 13.5 months against 22 months for patients without any alterations in both KRAS and CDKN2A.

doi:10.1371/journal.pone.0060870.g001
The ADM were purported to be the originating lesions for PDAC in mouse models [20]. Analysis of human ADM lesions showed that KRAS mutations existed only in the lesions associated with PanIN; the isolated ADM lesions were devoid of any KRAS mutation, with possible involvement of two distinct mechanisms, with and without KRAS mutations [19]. Those observations indicate that the presence of a KRAS mutation may not be essential for human PDAC progression and other low frequency gene mutations could trigger alternate pathways. The pancreatic genome sequencing of 20,661 genes from 24 tumors identified other low frequency gene mutations [21]. A recent study reported occurrence of 3–4 driver mutations in the KRAS, CDKN2A, TP53 and SMAD4 genes in about 30% of pancreatic tumors [15].

The codons 12, 13 and 61 of KRAS gene are part of the conserved ‘G-domain’ (residues 1–165) required for signal transduction. Tumor malignancy depends not on the presence of a conserved ‘G-domain’ (residues 1–165) required for signal transduction. Tumor malignancy depends on the presence of any constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22]. Our data in this study showed that presence of any KRAS mutation but on the molecular configuration and constituent mutation type [22].

In conclusion, our results show that mutations in KRAS are frequent but not universal in pancreatic tumors and the presence of KRAS mutations in general, and G12D transformation in particular, were indicative of association with poor survival. Our pancreas-specific and reversible expression of inducible KRAS G12D mutant was shown not only to initiate neoplastic lesions but was also involved in tumor maintenance [26]. In genetically engineered mice G12D mutant KRAS is reported to promote widespread colonic epithelia hyperplasia and neoplasia [27]. To best of our knowledge, this is the first report showing a clear association between KRAS mutation subtypes and survival. Our previous report on paraffin embedded tumors did not show any association between the presence of KRAS mutations and patient survival; however, there was difference in survival between the patients with different mutation types [14]. Lack of KRAS mutational status as predictive of survival was also reported in an earlier trial study of Gemcitabine and Erlotinib therapy in patients with advanced pancreatic cancer [28]. KRAS mutations in the surgically negative resected margins have also been shown to be associated with clinical cancer recurrence, aggressive tumor biology and poor survival [29]. Similarly, detection of KRAS mutations in retroperitoneal margins, in the patients with complete pancreatectomy also showed poor prognosis [29].

The other gene that has been consistently reported to carry high frequency of somatic mutation in pancreatic cancers is CDKN2A [30]. The deletion/mutation frequency of CDKN2A in the present study was in agreement with that reported in the COSMIC database [31]. A mouse model with a conditional knock-in and knock-out of Knas617D and Ink4a/Arf showed enhanced progression of pre-malignant lesions to PDAC [32,33]. In this study we found that the subset of patients with concomitant KRAS and CDKN2A aberrations were at 2.5-fold higher risk of death than patients without any alterations in the two genes. In a previous study it was shown that 1–2 mutations in pancreatic tumors showed a median survival of 23 months compared to 13 months in our present study [15]. The difference in median survival can be, possibly, attributed to the fact that 149 out of 159 patients in our study had stage III and IV tumors. Mice models have shown that survival times were dependent on genetic aberrations accompanying a KRAS mutation [34,35]. Similar results were reported in a study on KRAS mutations together with loss of heterozygosity on different chromosomal positions [29].

In conclusion, our results show that mutations in KRAS are frequent but not universal in pancreatic tumors and the presence of KRAS mutations in general, and G12D transformation in particular, were indicative of association with poor survival. Our

| Parameter | Total | Alive (censored) | Median Survival (95% CI) | P | Hazard ratio (HR)* | 95% CI |
|-----------|-------|-----------------|-------------------------|---|-------------------|--------|
| KRAS Wt   | 21    | 7               | 30 (12–44)              | 0.03 | 1.00 (reference) |
| KRAS mutants | 107  | 19              | 17 (13–21)              | 2.19 | 1.09–4.42         |
| KRAS G12D (GAT) | 60   | 9               | 16 (11–23)              | 0.98 | 1.42–2.67         |
| KRAS: G12R (CGT) | 22   | 5               | 18 (13–31)              | 0.04 | 0.39–2.73         |
| KRAS: G12V (GTT/GTC) | 20   | 4               | 16 (8–19)               | 0.08 | 2.38–992.70       |
| KRAS: Q61H (CAC) | 3     | 0               | 6 (4–35)                | 0.01 | 0.70–544.44       |
| K-ras others | 2     | 1               | 17 (–)                  | 0.03 | 126.13            |
| CDKN2A Wt | 98    | 22              | 19 (14–24)              | 1.00 | 1.42–11221.60     |
| CDKN2A mutants | 30   | 4               | 13.5 (9–18)             | 0.06 | 1.00 (reference)  |
| KRAS + CDKN2A wt | 17   | 6               | 22 (12–35)              | 1.00 | 1.00 (reference)  |
| KRAS + CDKN2A mutants | 26   | 3               | 13.5 (8–18)             | 0.01 | 3.07              |

* Hazard ratio and corresponding P-value for effect of mutations on survival calculated after adjusting with gender, age, TNM status, and tumor differentiation grade. doi:10.1371/journal.pone.0060870.t003
results also showed that concomitant occurrence of KRAS mutations and aberrations in CDKN2A resulted in a sub-group of patients with lowest survival. Our data from this study is suggestive for a case for the prognostic classification of pancreatic cancer patients based on mutational status of KRAS and CDKN2A. However, the results need independent confirmation in additional studies with definite statistical confidence.

Materials and Methods

Ethics Statement

For all samples analyzed, written informed consent was obtained from the patients. The study was approved by the local ethics committee of the University of Heidelberg.

Study population

Tumor tissues were collected from pancreatic cancer patients during surgery between January 2002 and September 2009, snap-frozen in liquid nitrogen directly after resection and subsequently stored at $-80 \degree C$. A total of 171 tumor tissues, that contained at least 10% tumor by H&E staining were analyzed in the present study. The clinical and histopathological characteristics of the patients are given in Table 1. The cell lines A549, SW1116, SW620, HS766T, MiaPaCa and LoVo were commercially obtained from American Type Culture collection (ATCC) [36,37].

Histopathological assessment of cellular composition of tissue biopsies

Three different tissue sections were selected randomly for hematoxylin and eosin (H&E) staining and histological validation. Slides were scanned with the ScanScope GL System (Aperio Technologies, Vista, CA, USA) and visualized using the ImageScope Software. For each tissue sample, three pathologists evaluated independently the histology and percentage of normal, tumor and stroma cells (Figure S1). Only samples with more than 10% tumor cells were pursued further.

Genomic DNA extraction

Frozen pancreatic tissue samples were individually cut into 20 μm thick slices with a cryotome Leica CM 1850 UV at $-34 \degree C$. The tissue slices were covered with liquid nitrogen and gently ground by three turns with a microspette made of polypropylene (Eppendorf, Hamburg, Germany) that fitted into 2 ml Eppendorf tubes. DNA from tissue slices and from cell lines was extracted using the AllPrep Isolation Kit (Qiagen, Hilden, Germany). DNA from cell lines with known KRAS mutations in codon 12, 13 and 61 were used as controls that included, A549 cell line with G12S (GGT→GAT) mutation; MiaPaCa, G12C (GGT→GTC); SW 1116, G12A (GGT→GCA) mutation; SW 620 G12V (GGT→GTG); LS-174, G12D (GGT→GAT); LoVo, G13D (GGC→GAC); HS 766T, Q61H (CAA→CAG). DNA samples from healthy controls were included as negative control.

PCR, single strand conformation polymorphism (SSCP) and sequencing

PCR was carried out in 10 μl reaction volumes using 10 ng of genomic DNA, 2 mM MgCl$_2$, 0.11 mM each dNTP, 1 μCi ($^{32}$P) dCTP, 0.2 μM each gene specific primer (Table S1), and 0.3 U Genaxxon Hot-start polymerase. The reactions were carried out in 35 cycles. Electrophoresis of the amplified fragments for SSCP was carried out on non-denaturing 0.5x MDE PAGE gels under at least 4 different conditions (Table S1). Each experiment was repeated twice and only when results were reproducible, shifted bands due to mutations were subjected to sequencing. The sequencing was carried out using a BigDye Terminator Cycle sequencing kit (Applied Biosystems). Amplified PCR product was treated with ExoSapIT (Amershams Biosciences, Uppsala, Sweden) and sequencing reactions were carried out in 10 μl reaction volumes using forward and reverse primers separately. The reaction products were analyzed on an ABI prism 3100 Genetic analyzer (Applied Biosystems).

Multiplex ligation-based probe amplification (MLPA)

MLPA was used to detect homozygous deletions at the CDKN2A locus using the MLPA ME024A kit (MRK-Holland, Amsterdam, The Netherlands) which contained 30 probes mapping chromosome 9p21 and 9p22, 13 reference probes and 9 internal controls. Reference probes were located in genomic regions with low frequency copy number changes. The hybridization and ligations were carried out as per instructions and fragment analysis was performed on an ABI PRISM 3130xl capillary sequencer. The data were visualized using peak scanner v1.0 software and the exported data was analyzed with Coffalyser software v8 (MRK-Holland, Amsterdam, the Netherlands). Calculation of signal ratios was carried out as described by Mistry et al. [38]. Stringent criteria were adopted for data analysis using Coffalyser software and experiments were repeated twice for reproducibility.

Statistical analyses

Of 171 tumors that were analyzed for mutations, 163 were malignant and 8 non-malignant tumors. Of the 163 patients with malignant tumors, survival data were available for 153 patients, of whom 150 patients had malignant tumors of pancreatic origin including ductal adenocarcinomas ($n=135$) and rare carcinomas ($n=15$). The rest ($n=3$) were carcinoma of ampulla of Vater (Table 1). The Kaplan–Meier method was employed to determine the cumulative survival curves using time period (in months) between date of operation and the date of death. Differences between the groups were analyzed by the log-rank test. Univariate and multivariate Cox regression analyses were used to determine proportional hazard ratios. For multivariate analysis variables included were gender, age at surgery, TNM status, tumor differentiation grade and histological status of tumors. All statistical analyses were carried out by using SAS® version 9.2 (SAS Institute Inc., Cary, NC).

Supporting Information

Figure S1 Histomorphological examination of pancreatic tumor tissue sections with Hematoxylin and Eosin stains. Representative photomicrographs of three sections with low, medium and high tumor contents are shown. (TIF)

Figure S2 Representative SSCP of KRAS codon 12 and codon 61 in pancreatic tumors. (A) The lanes 1–4 contain amplified fragments of exon 2 (codon 12) and lanes 5–6 contain amplified fragments of exon 3 (codon 61) from tumor DNA samples. The shifted bands seen in lane 1 contain GGT→GAT (G12D) mutation, lane 2 contains GGT→CGT (G12R), lane 3 contains GGT→GTT (G12V) mutation and lane 4 contains tumor DNA without mutation in exon 2. The shifted bands in lane 5 contain CAA→CAC (Q61H) mutation and lane 6 contains tumor DNA without mutation in exon 3. (B) Sequence analysis of a part of exon 2 of KRAS gene (coding strand) with GGT→GAT (G12D) mutation. (C) A part of exon 2 sequence showing GGT→CGT (G12R) mutation. (D) A part of exon 2 sequence showing GGT→GTT (G12V) mutation. (E) A part of the exon 2 showing...
wild type sequence at codon 12 and codon of KRAS. (F) A part of exon 3 sequence showing CAA>CAC (Q61H) mutation. (G) A part of the exon 3 showing the wild type sequence at codon 61 of KRAS. (TIF)

Figure S3 Kaplan-Meier survival curves showing difference in overall survival in exocrine cancer patients with and without mutations. (A) Median survival of patients with KRAS mutations was 17 months against 30 months for patients without mutations in the gene. (B) Median survival of patients with KRAS codon 12 GGT>GAT (G12D) mutations was 16 months against 30 months for patients without any mutation in KRAS. (C) Median survival of patients with concomitant alterations in KRAS and CDKN2A genes was 13 months against 30 months for patients without any alterations in both KRAS and CDKN2A. (TIF)

Table S1 Primer sequences and SSCP conditions for detection of mutations in the KRAS and CDKN2A genes.

(DOC)

References

1. Hruban RH, Pitman MB, Kilstra DS (2007) Tumors of the pancreas: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology.

2. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, et al. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17: 500–503.

3. Howard TJ (1996) Pancreatic adenocarcinoma. Curr Prob Clin Cancer 20: 281–328.

4. Maitra A, Hruban RH (2008) Pancreatic cancer. Annu Rev Pathol 3: 157–180.

5. Moore PS, Orlindini S, Zamboni G, Capelli P, Rügand G, et al. (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampulla but not in exocrine noductal or endocrine tumorigenesis. Br J Cancer 84: 253–262.

6. Benvenuti S, Arena S, Bardelli A (2005) Identification of cancer genes by mutational profiling of tumor genomes. FEBS Lett 579: 1084–1089.

7. Martini M, Vecchiione I, Siera S, Tejpar S, Bardelli A (2011) Targeted therapies: how personal should we go? Nat Rev Clin Oncol 8: 87–97.

8. Van Cutsem E, Kehne CH, Lang I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019.

9. Landi L, Cappuzzo F (2011) Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. Nat Rev Clin Oncol 8: 371–377.

10. Hayden EC (2011) Targeted treatment tested as potential cancer cure. Nature 479: 201.

11. Ribas A, Flaherty KT (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8: 426–433.

12. Haigis KM, Kendall RR, Wang Y, Cheung A, Haigis MC, et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600–608.

13. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, et al. (2008) Increased detection sensitivity for K-Ras mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 14: 4901–4914.

14. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, et al. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Investig 122: 639–653.

15. Haigis KM, Kendell RR, Wang Y, Cheung A, Haigis MC, et al. (2008) Mutational profiling of tumor genomes. FEBS Lett 579: 1884–1890.

16. Schneider G, Schmid RM (2005) Genetic alterations in pancreatic carcinomas. Mol Cancer 2: 15.

17. Nemes E, Zamboni G, Capelli P, Rügand G, et al. (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampulla but not in exocrine noductal or endocrine tumorigenesis. Br J Cancer 84: 253–262.

18. Yachida S, White C, Naito Y, Zhong Y, Brosnan JA, et al. (2012) Clinical implications of somatic mutations in K-Ras affecting MAPK pathway components in human tumors. Mol Cancer 2: 15.

19. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. (1994) Identification of Potential Long Term Survivors. Clin Cancer Res. 10: 1993–1999.

20. Shi C, Hong SM, Lim P, Kamiyama H, Khan M, et al. (2009) KRAS2 mutations in human pancreatic acinar-ductal metastatic lesions are limited to those with PanIN implications for the human pancreatic cancer cell of origin. Mol Cancer Res 7: 230–236.

21. Osterholz NA, Milne AN, Morsink HF, Drillingen P, Ten Kate EJ, et al. (2009) Pancreatic intraepithelial neoplasia and pancreatic tumorigenic of mice and men. Arch Path Lab Med 133: 375–381.

22. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.

23. Vizan P, Boros LG, Figuereza A, Capella G, Mangues R, et al. (2005) K-Ras codon-specific mutations produce distinctive metastatic phenotypes in NIH3T3 mice [corrected]. Fibrinol. Cancer Res 65: 5512–5515.

24. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with “K-Ras addiction” regulates the expression profile of EMT and tumor cell survival. Cancer Cell 15: 489–500.

25. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594–603.

26. Molinaro F, Felicioni L, Bucarino M, De Doss D, Battina F, et al. (2011) Increased detection sensitivity for K-Ras mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901–4914.

27. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, et al. (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Investig 122: 639–653.

28. Fukumura D, Chen DR, TAMAYO P, FEINBERG A, et al. (2008) Molecular predictors of outcome in a phase 3 trial of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA. Cancer 113: 5399–5407.

29. Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, et al. (2008) Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 12: 1664–1672; discussion 1672–1663.

30. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, et al. (1994) K-Ras oncogene subtype mutations are associated with survival but not expression of p53, p16INK4a, p27/WAF1, cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int J Cancer 80: 469–474.

31. Aoki H, Takahashi K, Yamamoto K, Kurokawa Y, Bessho Y, et al. (2001) Fas-inducible cell death mediated by Fas-ligand can be blocked by caspase-8-generated FLIP. J Biol Chem 276: 34580–34586.

32. Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer with mutations in EGFR. Nat Rev Clin Oncol 8: 571–573.

33. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, et al. (2005) A gene expression signature associated with “K-Ras addiction” regulates the expression profile of EMT and tumor cell survival. Cancer Cell 15: 489–500.

34. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12: 594–603.

35. Molinaro F, Felicioni L, Bucarino M, De Doss D, Battina F, et al. (2011) Increased detection sensitivity for K-Ras mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17: 4901–4914.

Acknowledgments

We acknowledge Sven Rüffer and Esther Soyka (Department of General Surgery, University of Heidelberg) for their assistance.

Author Contributions

Acquisition of data: PSR ASB HX DC CR SB WG EC MS AH AS JPN JW MB JDH NG RK. Development of methodology: PSR ASB HX SB WG EC MS AH AS JPN JW MB JDH NG RK. Conceived and designed the experiments: PSR ASB FC SB DC CR SB WG EC MS AH AS JPN JW MB JDH NG RK. Wrote the paper: PSR ASB HX DC CR FC SB WB EC MS AH AS JPN JW MB JDH NG RK.

Table S2 Mutation frequency by clinic pathology and effect on survival of pancreatic cancer patients.

(DOC)

Table S3 Clinico-pathological details and tumor mutational status of all pancreatic cancer patients.

(DOC)
36. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A, et al. (2009) Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol 78: 273–283.

37. Alhamdani MS, Schroder C, Hohensiel JD (2009) Oncoproteomic profiling with antibody microarrays. Genome Med 1: 68.

38. Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, et al. (2005) Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 44: 292–300.